Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/5/2020
SIETES contiene 93009 citas

 
 
<< anterior 21 a 40 de 499 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Bonanni B, Constantino JP, Cummings S, Decensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data1827-1834. Lancet 2013;381:1827-34. [Ref.ID 95506]
22.Tiene citas relacionadas
Howell A, Evans DG. Breast cancer prevention: SERMs come of age. Lancet 2013;381:1795-7. [Ref.ID 95498]
23. Cita con resumen
Nelson HD, Smith MEB, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:604-14. [Ref.ID 95272]
24.Enlace a cita original Cita con resumen
Anónimo. Ranelato de estroncio (Osseor, Protelos): riesgo de infarto agudo de miocardio. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2013:16 de abril. [Ref.ID 95186]
25.Tiene citas relacionadas Cita con resumen
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16. [Ref.ID 95085]
26.Tiene citas relacionadas
Powles TJ. Extended adjuvant tamoxifen for breast cancer—a new era?. Lancet 2013;381:782-3. [Ref.ID 95080]
27. Cita con resumen
Anónimo. FDA approves first oral dyspareunia treatment. DIA Daily 2013:27 de febrero. [Ref.ID 94708]
28. Cita con resumen
Freemantle N, Cooper C, Díez-Pérez A, Gitlin M, Radcliffe H, Shepherd S, Roux C. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013;24:209-17. [Ref.ID 94651]
29. Cita con resumen
Rahimy E, Sarraf D. Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema. Arch Ophthal 2012;130:931-2. [Ref.ID 92715]
30. Cita con resumen
31. Cita con resumen
Murad MH, Drake MT, Mullan RJ, Mauk KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012;97:1871-80. [Ref.ID 92114]
33. Cita con resumen
Anónimo. Prises de poids d'origine médicamenteuse. Prescrire 2011;31:748-52. [Ref.ID 91601]
34.Enlace a cita original
Anónimo. Tamoxifen: CYP2D6 interactions and variable clinical response. WHO Drug Information 2011;25:246. [Ref.ID 91490]
35.Tiene citas relacionadas
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84. [Ref.ID 91446]
36.Tiene citas relacionadas
Chia SK, Wolff AC. Whit maturity comes confidence: EBCTCG tamoxifen update. Lancet 2011;378:747-9. [Ref.ID 91445]
37. Cita con resumen
Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozzi F, Corradi D, Salvarani C, Buzio C. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011;378:338-46. [Ref.ID 91404]
38.Tiene citas relacionadas Cita con resumen
Anónimo. Tamoxifen and CYP 2D6 inhibitors: caution. Prescrire Int 2011;20:182-4. [Ref.ID 91095]
39. Cita con resumen
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Waclawski-Wende J, Mctiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farner P, Gelmon KA, Tu D, Richardson H, for the NCIC CTG MAP-3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91. [Ref.ID 90936]
40. Cita con resumen
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O0Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-81. [Ref.ID 90795]
Seleccionar todas
 
<< anterior 21 a 40 de 499 siguiente >>